Sankur Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 24-10-2024
- Revenue 10.05%
(FY 2023)
- Profit 10.34%
(FY 2023)
- Ebitda 19.55%
(FY 2023)
- Net Worth 28.98%
(FY 2023)
- Total Assets 23.67%
(FY 2023)
About Sankur Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.00 M.
Deepak Agarwal and Chirayush Singhal serve as directors at the Company.
- CIN/LLPIN
U74120UP2016PTC076748
- Company No.
076748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Agra, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sankur Pharmaceuticals Private Limited offer?
Sankur Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Animal Medicines & Health Care, Veterinary Bolus, Common Disease Medicines, Pharmaceutical Syrup, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Bird Food, Poultry & Animal Food, Animal Feed Supplement.
Who are the key members and board of directors at Sankur Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Agarwal  | Director | 23-Feb-2016 | Current |
| Chirayush Singhal | Director | 23-Feb-2016 | Current |
Financial Performance of Sankur Pharmaceuticals.
Sankur Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.05% increase. The company also saw a substantial improvement in profitability, with a 10.34% increase in profit. The company's net worth Soared by an impressive increase of 28.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sankur Pharmaceuticals?
In 2023, Sankur Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Envirobrace Sustainable Solutions Private LimitedActive 8 years 1 monthChirayush Singhal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 May 2023 | ₹4.00 M | Open |
How Many Employees Work at Sankur Pharmaceuticals?
Unlock and access historical data on people associated with Sankur Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sankur Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sankur Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
